Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Single Versus Multicenter Outcomes for Pelvic Organ Prolapse Repair Using a Mesh-capturing Device (KIDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03077490
Recruitment Status : Completed
First Posted : March 13, 2017
Last Update Posted : October 23, 2019
Sponsor:
Information provided by (Responsible Party):
Edward Morcos, Karolinska Institutet

Brief Summary:
Comparison of single versus multicenter outcomes for pelvic organ prolapse repair using a mesh-capturing device (The Uphold™ Vaginal Support System for apical and vaginal wall prolapse - Boston Scientific). 1-2 years follow up study comprison of 112 vs 207 patients.

Condition or disease Intervention/treatment
Prolapse Genital Device: Transvaginal mesh Uphold TM Vaginal Support System Device: Transvaginal mesh Uphold TM Vaginal Support System.

Detailed Description:

112 women operated by two surgeons at one center (2 years follow up) are to be compared to 207 women operated by twenty six surgeons at twenty four centers (1 year follow-up).

Screening at baseline for apical (uterine or vaginal vault) prolapse stage II with or without concomitant anterior or vaginal wall prolapse ≥ stage 2 according to the pelvic organ prolapse quantification (POP-Q) system.

Surgical data including operation data, complications and hospital stay are to be compared.

Anatomical outcome measurements by POP-Q evaluations. Subjective symptoms are to be evaluated by prolapse specific symptom questionnaires (PFIQ-7, UDI-6 and PFIQ) whereas sexual function to be estimated by PISQ-12.


Layout table for study information
Study Type : Observational
Actual Enrollment : 319 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Comparison of Single Versus Multicenter Outcomes for Pelvic Organ Prolapse Repair Using a Mesh-capturing Device
Actual Study Start Date : March 4, 2015
Actual Primary Completion Date : March 30, 2016
Actual Study Completion Date : February 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Single center vs. multicenter
Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
Device: Transvaginal mesh Uphold TM Vaginal Support System
Other Name: Transvaginal mesh Uphold TM Vaginal Support System.

Device: Transvaginal mesh Uphold TM Vaginal Support System.



Primary Outcome Measures :
  1. The rate of immediate complications [ Time Frame: From operation start to hospital discharge, assessed for an estimated total of days (1-7 days). ]
    Serious surgical complications are categorized as any surgical event which is potentially life-threatening related to the surgical procedure including: internal organ perforation (or other injury), bleeding in excess of 1000 mL.

  2. Rate of delayed complications [ Time Frame: From hospital discharge and up to 2 years at single center and 1 year at multicenter ]
    Adverse events during follow-up which requires re-hospitalisation or surgical re-intervention.


Secondary Outcome Measures :
  1. Anatomical outcomes [ Time Frame: 2 years vs 1 year ]
    Anatomical outcome is a composite definition including point C positioned above a point corresponding to half of the total vaginal length. The overall POP-Q outcomes will be analyzed to determine efficacy of the procedure related to correction of anterior prolapse ≥stage II or other defects present at the time of surgery. Days in hospital are counted from the day of surgery i.e. the day of operation is day 1 and the day of returning home is the last day of hospital stay.

  2. Subjective outcomes and sexual function [ Time Frame: 2 years vs 1 year ]
    Subjective outcome is the patients' response 'no' to question 2 of the PFDI (pelvic heaviness). The composite outcome is a strictly binary categorization where any residual sense of pelvic heaviness/vaginal bulging results in the classification of the patient as a failure. It also includes the components of the main secondary outcome considered individually, any adverse events in the aftermath of surgery, as well as, patient-reported urogenital distress (UDI), quality of life (PFIQ) and sexual function (PISQ-12) as measured by the self-reported questionnaires. For secondary analyses, the ordinal grading of responses to the PFDI-20, PFIQ-7 and PISQ-12 will be used to determine rates of improvement and progression over time.

  3. Ultrasound mapping of mesh position in the pelvic floor and correlation to anatomical and subjective outcomes and sexual function [ Time Frame: 5, 7, 10 years ]

    Mesh measurements: Total mesh midsagittal length, length above and below the bladder neck (BN) level. Distance between mesh lower edge and pubis symphysis (PS) lower edge and PS level.

    Bladder neck: Distance between BN and PS levels. Distance between BN and PS lower edge.

    Urethra: Total urethra length. Distance between mid-urethra and PS lower edge and PS level.

    Using identical examination protocol, independent examination at rest and physical strain is to be done by senior gynecologist at an ultrasound referral unit and gynecologist. Estimation of intra class coefficient (ICC) in-between examiners in order to determine method reproducibility.

    To statistically compare between the collected ultrasound data and clinical outcomes. Clinical outcomes include anatomical, subjective and sexual function outcome.


  4. Measurement of Pain by patient self-reporting Visual analogue scale (VAS-scale) [ Time Frame: Changes from baseline, 2, 5 and 10 years after surgery ]
    VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of pain.

  5. Measurement of urinary incontinence by patient self-reporting Visual analogue scale (VAS-scale) [ Time Frame: Changes from baseline, 2, 5 and 10 years after surgery ]
    VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of severity of urinary incontinence. VAS scale for urinary incontinence: 0 indicate no urinary incontinence whereas 10 indicates maximal or severe urinary incontinence.

  6. Measurement of patient satisfaction by patient self-reporting Visual analogue scale (VAS-scale) [ Time Frame: assessment at 2, 5 and 10 years after surgery ]
    VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of satisfaction after mesh surgery. VAS scale for patient satisfaction: 0 indicates no satisfaction whereas 10 indicates maximal satisfaction.

  7. 12. Measurement of patient recommendation to other patients to undergo same surgery with vaginal mesh if they suffer apical prolapse, assessed by patient self-reporting Visual analogue scale (VAS-scale) [ Time Frame: assessment at 2, 5 and 10 years after surgery ]
    VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of satisfaction. VAS scale for patient recommendation to other patients to undergo same surgery if they suffer apical prolapse: 0 indicates no recommendation whereas 10 indicates maximal recommendation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Sampling Method:   Non-Probability Sample
Study Population
112 patients from single center compared to 207 patients from 24 different centers
Criteria

Inclusion

  • Posthysterectomy prolapse of the vaginal apex, with or without cystocele, where the vaginal apex descends at least 50% of the total vaginal length
  • Uterine prolapse, with or without cystocele, where the leading edge of the cervix descends at least 50% of the total vaginal length and TVL minus point C= ≤ 2 cm
  • Prolapse specific pelvic symptom of pelvic heaviness and/or vaginal bulging
  • Reproductive years in the past (biologically or reproductive decision)
  • Being able to make an informed consent on participation
  • Physically and cognitively capable of participating in the required follow-up
  • No exclusion criteria fulfilled

Exclusion Criteria:

  • Posthysterectomy prolapse of the vaginal apex where the vaginal apex descends less than 50% of the total vaginal length regardless of whether a cystocele is present or not
  • Uterine prolapse, with or without cystocele, where the leading edge of the cervix descends less than 50% of the total vaginal length
  • If cervix elongation is present corresponding to: TVL minus point C= >2 cm.
  • If prolapse specific pelvic symptoms of pelvic heaviness and/or vaginal bulging are not present
  • Previous or current pelvic organ cancer (regardless of treatment)
  • Severe rheumatic disease
  • Insulin treated diabetes mellitus
  • Connective tissue disorders (SLE, Sjögrens syndrome, Marfans syndrome, Ehlers Dahnlos, collagenosis, polymyositis eller rheumatic myalgia)
  • Current systemic steroid treatment
  • Other clinically relevant pelvic disorders for which surgery is indicated including stress urinary incontinence, cervix elongation and posterior prolapse
  • Decision to perform prolapse surgery using other medical devices/mesh

Layout table for additonal information
Responsible Party: Edward Morcos, Senior consultant, MD, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT03077490     History of Changes
Other Study ID Numbers: Protokoll Dnr 2015/5: 3
First Posted: March 13, 2017    Key Record Dates
Last Update Posted: October 23, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Edward Morcos, Karolinska Institutet:
Pelvic organ prolapse
transvaginal mesh
complications
Additional relevant MeSH terms:
Layout table for MeSH terms
Prolapse
Pelvic Organ Prolapse
Pathological Conditions, Anatomical